Molecular and Cellular Biology, December 1998, p. 7147-7156, Vol. 18, No. 12
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Division of Laboratory Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030,1 and University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey 088542
Received 14 April 1998/Returned for modification 7 June 1998/Accepted 19 August 1998
The promyelocytic leukemia protein (PML) is a nuclear
phosphoprotein with growth- and transformation-suppressing ability. Having previously shown it to be a transcriptional repressor of the
epidermal growth factor receptor (EGFR) gene promoter, we have now
shown that PML's repression of EGFR transcription is caused by
inhibition of EGFR's Sp1-dependent activity. On functional analysis,
the repressive effect of PML was mapped to a 150-bp element (the
sequences between
150 and
16, relative to the ATG initiation site)
of the promoter. Transient transfection assays with Sp1-negative
Drosophila melanogaster SL2 cells showed that the
transcription of this region was regulated by Sp1 and that the
Sp1-dependent activity of the promoter was suppressed by PML in a
dose-dependent manner. Coimmunoprecipitation and mammalian two-hybrid
assays demonstrated that PML and Sp1 were associated in vivo. In vitro
binding by means of the glutathione S-transferase (GST)
pull-down assay, using the full-length and truncated GST-Sp1 proteins
and in vitro-translated PML, showed that PML and Sp1 directly
interacted and that the C-terminal (DNA-binding) region of Sp1 and the
coiled-coil (dimerization) domain of PML were essential for this
interaction. Analysis of the effects of PML on Sp1 DNA binding by
electrophoretic mobility shift assay (EMSA) showed that PML could
specifically disrupt the binding of Sp1 to DNA. Furthermore,
cotransfection of PML specifically repressed Sp1, but not the
E2F1-mediated activity of the dihydrofolate reductase promoter.
Together, these data suggest that the association of PML and Sp1
represents a novel mechanism for negative regulation of EGFR and other
Sp1 target promoters.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|